Emmessar Biotech reappoints MD and WTD at 34th AGM

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Emmessar Biotech & Nutrition Limited held its 34th AGM on September 29, 2026, via video conferencing
  • Special resolutions approved the five-year re-appointment of Srinivasa Raghavan Mathurakavi Ayyangar as Managing Director
  • Jeyavel Balaiah Nadar was re-appointed as Whole Time Director for a further period of five years
  • Remote e-voting results are expected to be announced within 48 hours of the scrutinizer's report
powered bylight_fuzz_icon
52211052

*this image is generated using AI for illustrative purposes only.

Emmessar Biotech & Nutrition Limited concluded its 34th Annual General Meeting on September 29, 2026, with members approving key leadership appointments. The meeting was conducted through Video Conferencing and Other Audio Visual Means, ensuring continuity in corporate governance protocols.

The shareholders passed special resolutions to re-appoint Srinivasa Raghavan Mathurakavi Ayyangar as Managing Director and Jeyavel Balaiah Nadar as Whole Time Director for a further period of five years. Additionally, Nadar was re-appointed as a Director retiring by rotation under an ordinary resolution.

Governance and voting procedures

The meeting commenced at 10:30 am with Srinivasa Raghavan Mathurakavi Ayyangar elected as Chairman. The requisite quorum was present, allowing the Chairman to call the meeting to order. The Company Secretary briefed members on procedural aspects, and the Notice of the Meeting was taken as read with member permission.

Remote e-voting facilities were provided by MUFG Intime India Private Limited (formerly Linkintime India Private Limited). The voting window opened at 9:00 am on September 26, 2026, and closed at 5:00 pm on September 28, 2026. During the live meeting, e-voting remained open for 15 minutes after the formal closure to allow participating members to cast their votes.

Resolutions transacted

The following business items were transacted during the annual general meeting:

Item No Particulars Resolution Type
1 Adoption of Audited Financial Statements for FY26 along with Board and Auditor reports Ordinary
2 Re-appointment of Jeyavel Balaiah Nadar (DIN: 08163899) as Director Ordinary
3 Re-appointment of Srinivasa Raghavan Mathurakavi Ayyangar (DIN: 00090266) as Managing Director for 5 years Special
4 Re-appointment of Jeyavel Balaiah Nadar (DIN: 08163899) as Whole Time Director for 5 years Special

Tribhuwneshwar B. Kaushik, or in his absence Savyasachi Joshi, from Kaushik Joshi & Co., served as scrutinizers. The results of the remote e-voting and on-site e-voting are scheduled for announcement within 48 hours of receiving the scrutinizer's report. The meeting officially concluded at 10:56 am.

Historical Stock Returns for Emmessar Biotech

1 Day5 Days1 Month6 Months1 Year5 Years
+5.74%-0.08%-4.16%-0.29%-29.46%-28.29%

How will the five-year continuity of the current leadership team influence Emmessar Biotech's strategic direction regarding R&D investments and market expansion?

What specific operational milestones or financial targets has the re-appointed Managing Director outlined for the upcoming fiscal years to justify the extended tenure?

How might the stable governance structure impact institutional investor confidence and the company's valuation in the near-term biotech sector?

Emmessar Biotech to hold AGM on Sept 29; reappoints MD, WTD

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • Emmessar Biotech schedules its 34th AGM for September 29, 2026
  • Shareholders to reappoint MD Srinivasa Raghavan Mathurakavi Ayyangar for five years
  • WTD Jeyavel Balaiah Nadar seeks reappointment until February 2031
  • Remote e-voting opens on September 26 with a cutoff date of September 22
powered bylight_fuzz_icon
50075645

*this image is generated using AI for illustrative purposes only.

Emmessar Biotech has scheduled its 34th Annual General Meeting for September 29, 2026. The meeting will be conducted via video conferencing or other audio-visual means, as permitted by Ministry of Corporate Affairs circulars.

The primary agenda involves the reappointment of key management personnel. Shareholders will vote on the five-year reappointment of Srinivasa Raghavan Mathurakavi Ayyangar as Managing Director and Jeyavel Balaiah Nadar as Whole-time Director.

Management Reappointments

The Board proposes extending the tenure of Mr. Ayyangar from April 20, 2027, to April 19, 2032. His proposed monthly salary scale ranges from ₹2,20,000 to ₹4,00,000. Perquisites are capped at 50% of his salary and include housing, medical benefits, and club memberships.

Mr. Nadar’s reappointment covers the period from February 6, 2026, to February 5, 2031. His proposed salary scale is set between ₹1,20,000 and ₹2,50,000 per month. The resolution also seeks ratification of his acts and remuneration up to the date of the resolution.

Director Role Tenure Period Proposed Salary Scale (Monthly)
Srinivasa Raghavan Mathurakavi Ayyangar Managing Director April 20, 2027 – April 19, 2032 ₹2,20,000 – ₹4,00,000
Jeyavel Balaiah Nadar Whole-time Director February 6, 2026 – February 5, 2031 ₹1,20,000 – ₹2,50,000

Governance and Voting

Mr. Jeyavel Balaiah Nadar also retires by rotation and offers himself for re-appointment as a Director. The company confirmed compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, by sending separate letters to shareholders without registered email addresses.

Remote e-voting will commence on September 26, 2026, at 9:00 am and conclude on September 28, 2026, at 5:00 pm. The record date for voting rights is September 22, 2026. Institutional shareholders must upload board resolutions authorizing their representatives to vote.

Historical Stock Returns for Emmessar Biotech

1 Day5 Days1 Month6 Months1 Year5 Years
+5.74%-0.08%-4.16%-0.29%-29.46%-28.29%

How might the five-year tenure extension for the Managing Director influence Emmessar Biotech's long-term strategic roadmap and R&D pipeline stability?

What is the market's likely reaction to the proposed salary scales for key management, particularly in comparison to peer companies in the biotech sector?

Could the reappointment of Jeyavel Balaiah Nadar signal any upcoming shifts in corporate governance or operational focus for the company?

More News on Emmessar Biotech

1 Year Returns:-29.46%